This registry aims to assess real-world long-term disease outcomes for patients treated using reversible electroporation and a chemotherapeutic or calcium; in particular tumour response rates and recurrence rates. The study also aims to characterise side effects and the occurrence of Adverse Events and their relationship to the treatment.
Study Type
OBSERVATIONAL
Enrollment
1,000
Royal London Hospital
London, United Kingdom
RECRUITINGIncidence of Treatment-Emergent Adverse Events (CTCAE)
Safety evaluation will be performed via continuous assessment of safety parameters by reviewing events as they arise. The investigation will be put on hold if unacceptable safety issues are outstanding. Adverse Events (AE) and Serious Adverse Events (SAE) will be evaluated and graded according to Common Terminology Criteria for Adverse Events (CTCAE)
Time frame: 5 years
Response Evaluation Criteria in Solid Tumours (RECIST)
A response evaluation will be conducted at standard of care follow up
Time frame: 3 months, 12 months, 3 years, 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.